Clinical trial
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive…
NCT00058019 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00058019 |
|---|---|
| Title | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin's Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | ixabepilone |
| Enrollment | 51 |
| Start date | Feb 1, 2003 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Apr 9, 2003 |
| Last update posted | May 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: